ArticleClinical oral investigations2025
The in vitro antibacterial efficacy of advanced platelet-rich fibrin plus supplemented with metronidazole against Fusobacterium nucleatum.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOwing to its high antibacterial efficacy and low adverse effects, local antibiotic administration has attracted attention. This in vitro study compares the antibacterial effectiveness of advanced platelet-rich fibrin plus (A-PRF+) combined with metronidazole produced under different protocols. MATERIALS AND
methodsEight volunteers participated in this study. A 0.02% metronidazole was supplemented into A-PRF + based on four protocols concerning time (before vs. after centrifugation) and dosages (0.25 vs. 0.50 mL), yielding four groups: B25 (before centrifugation, 0.25 mL), B50 (before centrifugation, 0.50 mL), A25 (after centrifugation, 0.25 mL), and A50 (after centrifugation, 0.50 mL). Agar diffusion experiments on Fusobacterium nucleatum strain ATCC 25,586 were conducted to determine the bacterial efficacy of the four groups on three time points: day 2 (D2), D3 and D4. Images of the bacterial inhibition zone (BIZ) at assessment times were captured to measure BIZ dimensions using ImageJ software.
resultsNo significant difference was found between the BIZs of B25 and B50; however, the BIZs of A50 were significantly higher than those of A25. BIZs of each group tend to decrease, although no significant difference was found. Two-way repeated measures ANOVA revealed a significant interaction between the timing and observation time points. Post-hoc analysis showed that at each observation time point, BIZs of A-PRF + combined with metronidazole after centrifugation were significantly higher than those before, regardless of the dosage.
conclusionThe results of this study suggest that supplementing metronidazole into A-PRF + after centrifugation provides better antibacterial efficacy against Fusobacterium nucleatum than before centrifugation. CLINICAL RELEVANCE: A-PRF + supplemented with metronidazole after centrifugation can exert better antibacterial efficacy against Fusobacterium nucleatum.
Indexed as
Identifiers
40562975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.